Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 1/20 | 0.52 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.48 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.43 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.43 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.43 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.43 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2861358 | 0.87 | PLA2G10 (0.55) | PLA2G10PLA2G2APARP10CYP17A1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30503518 | 0.85 | BLM (0.56) | PLA2G10PLA2G2APARP10CYP17A1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2386467 | 0.85 | BLM (0.56) | PLA2G10PLA2G2APARP10CYP17A1ALDH1A1 | |
| SCHEMBL5105933 | 0.83 | OPRM1 (0.50) | PLA2G10PLA2G2APARP10OPRM1OPRD1 | |
| SCHEMBL6797264 | 0.83 | RARB (0.59) | ESR1CYP19A1ESR2ALDH1A1KMT2A | |
| SCHEMBL6933368 | 0.83 | CYP4A11 (0.59) | PLA2G10PLA2G2APARP10CYP17A1ALDH1A1 | |
| Terephthalamide SCHEMBL2427678 | 0.82 | PARP10 (0.50) | PLA2G10PLA2G2APARP10ALDH1A1KMT2A | |
| Terephthalamide SCHEMBL549164 | 0.82 | PARP10 (0.50) | PLA2G10PLA2G2APARP10ALDH1A1KMT2A | |
| Terephthalamide SCHEMBL29162705 | 0.82 | PARP10 (0.50) | PLA2G10PLA2G2APARP10ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL11111164 | 0.82 | RARB (0.58) | ESR1CYP19A1ESR2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635821-B1 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL)AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARM INC (US) | 2009-07-08 | — | — | EP | claimed |
| US-20070123531-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. | 2007-05-31 | — | — | US | claimed |
| EP-1635821-A2 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL)AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Elan Pharmaceuticals, Inc. (US) | 2006-03-22 | — | — | EP | claimed |
| US-20050032868-A1 | Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | claimed |
| WO-2004099155-A2 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL) AMIDE DERIVATES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | claimed |
| US-20220165952-A1 | NANOPARTICLE, METHOD FOR PATTERNING NANOPARTICLE LAYER AND LIGHT EMITTING DEVICE | BOE TECHNOLOGY GROUP CO., LTD. (CN) | 2022-05-26 | — | — | US | disclosed |
| CN-110041273-A | 2- (the chloro- 4- aminomethyl phenyl of 2-) quinazoline -4 (3H) -one class compound and its medical usage | 中国人民解放军军事科学院军事医学研究院 | 2019-07-23 | — | — | CN | disclosed |
| US-9716235-B2 | 9,10-bis[2-(p-substituted phenyl)pyrimidin-4-yl] anthracene compounds, methods of preparing the same, organic electroluminescent devices and organic electroluminescent display apparatus | BOE TECHNOLOGY GROUP CO., LTD. (CN) | 2017-07-25 | — | — | US | disclosed |
| US-20150214487-A1 | 9,10-Bis[2-(p-substituted phenyl)pyrimidin-4-yl] Anthracene Compounds, Methods of Preparing the Same, Organic Electroluminescent Devices and Organic Electroluminescent Display Apparatus | BOE TECHNOLOGY GROUP CO., LTD. (CN) | 2015-07-30 | — | — | US | disclosed |
| EP-1635821-B1 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL)AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARM INC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20070123531-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. | 2007-05-31 | — | — | US | disclosed |
| EP-1635821-A2 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL)AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Elan Pharmaceuticals, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20050032868-A1 | Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | disclosed |
| WO-2004099155-A2 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL) AMIDE DERIVATES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| EP-0255415-A2 | Use of phenylethanolamines for the preparation of medicaments acting on gastrointestinal troubles | ELF SANOFI (FR) | 1988-02-03 | — | — | EP | disclosed |
| US-4585796-A | HYPOGLYCEMIC, ANTI-OBESITY | HOFFMANN-LA ROCHE INC. (US) | 1986-04-29 | — | — | US | disclosed |
| EP-0047536-B1 | SUBSTITUTED PROPYLAMINES | ELI LILLY AND COMPANY (US) | 1984-06-27 | — | — | EP | disclosed |
| EP-0007206-B1 | PHENETHANOLAMINES, THEIR FORMULATIONS, PREPARATION AND USE | ELI LILLY AND COMPANY (US) | 1983-02-23 | — | — | EP | disclosed |
| EP-0062827-A2 | Novel benzamide derivatives | KYOWA HAKKO KOGYO CO., LTD (JP) | 1982-10-20 | — | — | EP | disclosed |
| EP-0047536-A2 | Substituted propylamines | ELI LILLY AND COMPANY (US) | 1982-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123531-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | BDKRB1, BDKRB2, LTB4R | PLA2G10 2436/4885PLA2G2A 1450/4885PARP10 1241/4885 |
| US-20050032868-A1 | Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | BDKRB1, BDKRB2, BRS3 | PLA2G10 2900/4885PLA2G2A 2092/4885PARP10 1034/4885 |
| US-20150214487-A1 | 9,10-Bis[2-(p-substituted phenyl)pyrimidin-4-yl] Anthracene Compounds, Methods of Preparing the Same, Organic Electroluminescent Devices and Organic Electroluminescent Display Apparatus | P2RY10, P2RY4, APRT | PLA2G10 883/4885PLA2G2A 1433/4885PARP10 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.